Grifols, S.A. (GRFS) is in Healthcare, Drug Manufacturers - General, based in Spain, listed on NasdaqGS. Market cap 5.04B USD. 52-week range 6.96 to 9.90 USD. Trailing P/E 9.6. Data as of 2026-10-09.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic ...